AI device cleared by FDA to spot lesions during colonoscopyThe FDA has approved the first artificial intelligence-powered device that can be used to help identify colorectal lesions Share XAI device cleared by FDA to spot lesions during colonoscopyhttps://pharmaphorum.com/news/ai-device-cleared-by-fda-to-spot-lesions-during-colonoscopy/
Update: J&J COVID vaccine rollout paused as clot concerns spreadUS health authorities have recommended pausing dosing with Johnson & Johnson’s COVID-19 vaccine as they investigate cases of Share XUpdate: J&J COVID vaccine rollout paused as clot concerns spreadhttps://pharmaphorum.com/news/us-seeks-halt-on-jj-covid-vaccine-rollout-as-clot-concerns-spread/
Scotland opens door to Translarna for Duchenne muscular dystrophyA disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland Share XScotland opens door to Translarna for Duchenne muscular dystrophyhttps://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/
Apple, Google block NHS contact tracing app update on privacy groundsA scheduled update to the NHS COVID-19 app has been blocked because it allows location tracking – something Share XApple, Google block NHS contact tracing app update on privacy groundshttps://pharmaphorum.com/news/apple-google-block-nhs-contact-tracing-app-update-on-privacy-grounds/
AstraZeneca’s Farxiga fails phase 3 COVID-19 testHope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed Share XAstraZeneca’s Farxiga fails phase 3 COVID-19 testhttps://pharmaphorum.com/news/astrazenecas-farxiga-fails-phase-3-covid-19-test/
Exscientia starts trials of first AI-derived cancer immunotherapyExscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) Share XExscientia starts trials of first AI-derived cancer immunotherapyhttps://pharmaphorum.com/news/exscientia-starts-trials-of-first-ai-derived-cancer-immunotherapy/
Provention faces delay in FDA review of diabetes prevention antibodyThe FDA says it has uncovered “deficiencies” in the marketing application for Provention Bio’s much-anticipated drug teplizumab for Share XProvention faces delay in FDA review of diabetes prevention antibodyhttps://pharmaphorum.com/news/provention-faces-delay-in-fda-review-of-diabetes-prevention-antibody/
Lilly’s Olumiant flunks COVID-19 trial – or does it?Eli Lilly’s JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 Share XLilly’s Olumiant flunks COVID-19 trial – or does it?https://pharmaphorum.com/news/lillys-olumiant-flunks-covid-19-trial-or-does-it/
Healx deploys its AI in hunt for Friedreich’s ataxia therapiesUK artificial intelligence specialist Healx has begun a partnership with two medical charities that aims to uncover new Share XHealx deploys its AI in hunt for Friedreich’s ataxia therapieshttps://pharmaphorum.com/news/healx-deploys-its-ai-in-hunt-for-friedreichs-ataxia-therapies/
